Researchers were shocked when the FDA started investigating whether CAR-T therapy could cause lymphoma, a rare type of cancer. Although there is no definitive evidence that CAR-T therapy directly causes new cancers, there have been a few cases of T cell lymphoma in patients previously treated with CAR-T cells. Studies have shown that the risk of developing a secondary malignancy after CAR-T therapy is relatively low, and researchers are still trying to understand the underlying factors contributing to this risk. Overall, the benefits of CAR-T therapy outweigh the risks for most patients, but ongoing monitoring and research are necessary to improve safety and outcomes.
Source link
CAR-T cell therapy’s risks and benefits are becoming clearer
